Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in China
April 22, 2022 04:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 22 April 2022 at 11.30 EEST Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in China Submission to the Center...
Liisa Hurme appointed President and CEO of Orion Corporation as of 1 November 2022
April 20, 2022 01:30 ET
|
Orion Oyj
ORION CORPORATION STOCK EXCHANGE RELEASE – INSIDE INFORMATION20 APRIL 2022 at 8:30 a.m. EEST Liisa Hurme appointed President and CEO of Orion Corporation as of 1 November 2022 ...
Orion is planning to refocus its R&D – in the future focus would be on cancer and pain
March 24, 2022 05:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 24 March 2022 at 11.30 a.m. EET Orion is planning to refocus its R&D – in the future focus would be on cancer and pain Orion is...
Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in Japan
March 11, 2022 01:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 11 March 2022 at 8.30 EET Orion’s collaboration partner Bayer submits application for additional indication of darolutamide in Japan Submission to the Ministry...
Orion’s collaboration partner Bayer submits applications in the U.S. and EU for additional indication of darolutamide
March 09, 2022 01:30 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE 9 March 2022 at 8.30 EET Orion’s collaboration partner Bayer submits applications in the U.S. and EU for additional indication of darolutamide Submissions in...
Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with metastatic hormone-sensitive prostate cancer
February 17, 2022 16:32 ET
|
Orion Oyj
ORION CORPORATION PRESS RELEASE17 FEBRUARY 2022 at 23.32 EET Darolutamide plus androgen deprivation therapy and docetaxel significantly increases overall survival in patients with...
Orion’s collaboration partner Bayer upgrades estimate on Nubeqa®’s peak sales potential
February 17, 2022 16:32 ET
|
Orion Oyj
ORION CORPORATION INSIDE INFORMATION / STOCK EXCHANGE RELEASE 17 FEBRUARY 2022 at 23.32 EET Orion’s collaboration partner Bayer upgrades estimate on Nubeqa®’s peak sales...
Orion Group Financial Statement Release for 2021
February 10, 2022 05:00 ET
|
Orion Oyj
ORION CORPORATION FINANCIAL STATEMENT RELEASE 2021 10 FEBRUARY 2022 at 12:00 Orion Group Financial Statement Release for 2021 This is a summary or Orion’s Financial Statement Release...
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
December 03, 2021 01:30 ET
|
Orion Oyj
ORION CORPORATION STOCK EXCHANGE RELEASE / INSIDE INFORMATION3 DECEMBER 2021 at 8.30 EET ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation...
Global Castrate Resistant Prostate Cancer (CRPC) Market to Surpass US$ 16.4 Billion by 2028, Says Coherent Market Insights (CMI)
July 20, 2021 08:40 ET
|
CMI
SEATTLE, July 20, 2021 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global castrate-resistant prostate cancer market is estimated to be valued at US$ 9.5 billion in 2021 and is...